Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2002
Industry: Medical Devices (Less-invasive interventional procedures)
Boston Scientific is a global developer, manufacturer, and marketer of less-invasive medical devices used in interventional cardiology, peripheral intervention, neurovascular, electrophysiology, vascular surgery, gastroenterology, gynecology, oncology, and urology. The company operates through two primary business groups: Cardiovascular (approx. 68% of sales) and Endosurgery (approx. 32% of sales). International sales accounted for approximately 40% of net sales in 2002.
Key Financial Metrics
Revenue: Net sales exceeded $2.9 billion in 2002, a substantial increase from $1.8 million in 1979.
Research & Development: Approximately $343 million, representing 12% of net sales.
Market Capitalization: Approximately $9.1 billion (based on non-affiliate holdings as of June 28, 2002).
Stock Price: $47.40 (closing price March 21, 2003).
Shares Outstanding: 409,947,858 (as of March 21, 2003).
Employees: Approximately 13,900 as of December 31, 2002.
Note: Specific figures for net income, operating cash flow, total debt, and liquidity ratios are not provided in the text of this filing summary; they are incorporated by reference in the Consolidated Financial Statements (Exhibit 13.1).
Material Changes and Strategic Developments
- Product Leadership: Regained leadership in cardiovascular and peripheral vascular catheter labs with the launch of the Express(2) coronary stent system and the Maverick balloon dilatation catheter (market leader).
- Drug-Eluting Stents (TAXUS): Significant investment in the TAXUS paclitaxel-eluting stent program. Clinical trials (TAXUS I-IV) showed promising results in reducing restenosis. The FDA granted "expedited review" status in March 2003, with a U.S. launch expected in late 2003.
- Acquisitions: Completed acquisitions of BEI Medical Systems (women's health), Enteric Medical Technologies (GERD treatment), and Smart Therapeutics (neurovascular stents).
- Operational Restructuring: Completed a plant optimization initiative, consolidating manufacturing and displacing approximately 1,950 employees. Shifted production to Miami, Ireland, and contract manufacturers.
- Branding: Announced a master branding initiative to unify divisional identities under the "Boston Scientific" name, effective in 2003.
Outlook, Risks, and Contingencies
Guidance and Outlook: Management anticipates R&D expenses to remain at approximately 12% of net sales in 2003. The company expects the drug-eluting stent market to grow to $5 billion by 2005. The company is transitioning to a nine-business operating structure in 2003.
Legal Proceedings:
- Patent Litigation: Active disputes with Johnson & Johnson (regarding Cypher and Express(2) stents), Guidant Corporation (regarding Express stents and delivery systems), and Medinol Ltd. These involve claims of infringement and counterclaims seeking injunctions and monetary relief.
- FTC Judgment: A judgment of approximately $7 million was entered against the company on March 28, 2003, regarding a 1995 Consent Order violation. The company is evaluating an appeal.
Risks:
- Regulatory: Delays in FDA or international approvals for new products, particularly the TAXUS stent.
- Market: Intense competition in the coronary stent market; uncertainty regarding physician adoption rates and reimbursement policies for drug-eluting stents.
- International: Foreign currency fluctuations and economic pressures in key markets like Japan and Europe.
- Liability: The company became substantially self-insured for general and product liability claims in Q3 2002, exposing it to potential catastrophic losses.
Investor Verification Checklist
- Verify the specific net income, operating cash flow, and debt levels in the Consolidated Financial Statements (Exhibit 13.1) as these are not detailed in the text.
- Monitor the status of the FDA Pre-Market Approval (PMA) for the TAXUS drug-eluting stent, specifically the submission of the final module containing TAXUS IV data.
- Track the outcomes of pending patent litigation with Johnson & Johnson and Guidant, as adverse rulings could impact market access and profitability.
- Assess the impact of the $7 million FTC judgment and the decision to appeal.
- Review the integration progress of recent acquisitions (BEI, Enteric, Smart) and the operational savings from the plant optimization initiative.